The Role of Cardiac Screening for CLL Patients on Ibrutinib

Ibrutinib transformed treatment for chronic lymphocytic leukemia (CLL) when introduced in 2014. While it continues to be widely used, the Bruton’s tyrosine kinase (BTK) inhibitor is associated with a significant risk of cardiac adverse events, particularly cardiac arrhythmias.

VA Researchers Illuminate a New Blood Cancer, a Novel Type of CLL

In the case of chronic lymphocytic leukemia (CLL) with prolymphocytic progression, a newly defined and very rare type of cancer, the scale of the VA and the number of patients it treats with leukemia allowed VA researchers to describe the characteristics and progression of the disease and begin to understand how it responds to current therapies.

Should All Thyroid Incidentalomas Be Evaluated?

It is not unusual for a clinician to identify thyroid incidentalomas on non-thyroid dedicated imaging studies. However, discovered, clinical guidelines recommend evaluation of all thyroid incidentalomas to risk-stratify for cancer.